The 3 Biggest Factors for Success in Value-Based Care
Novel therapies can spend decades in the development cycle only to have their therapeutic promise curtailed by lack of enrolment. Recruitment challenges underpin more than 60% of clinical trial failures — with significant costs borne both by the life sciences industry and the unaddressed disease burden of patients that are in dire need of these life-saving therapies.
The use of patient journey complete datasets from payers allows a novel approach using robust administrative data signals to identify providers that have screening eligible patients. Payer complete datasets contain enough population stability to correctly define the care journeys of screening eligible patients and find similar patients that have a high likelihood of disease.
In our talk, we will share the story of partnering on a phase 3 clinical trial that accelerated recruitment by over 18 months and the lessons that can be learnt as an industry.
Finally, we will discuss the future of data in clinical trials — looking at synthetic control arms as a stepping stone to larger applications of data. The complete actualization of data’s potential could reshape our industry and significantly ameliorate the disease burden of at-risk populations across the therapeutic spectrum.
Learning Objectives:
- How leveraging patient journey complete data sets differ from legacy data
- Why traditional bibliometrics represents a uni-dimensional view of the provider/site landscape
- Best practices for evaluating data partners and making data-driven clinical development programs successful
Speaker Panel:
Peggy Chou, MD, MBA
Senior Medical Director, Medical Management and ACO Population Management
Atrius Health
Natalie Lukaszewicz
Vice President, Network Development and Contracting
Buckeye Health Plan
Mike Funk
Health Affairs and Advocacy
Humana
Mike Fay
Vice President, Health Networks and Innovation
Wellmark
James Lawson
Executive Vice President of Business Development and Marketing
Nascate
